# Curi Bio

> Curi Bio is a Seattle biotechnology company building human-relevant preclinical platforms for drug discovery. By combining human iPSC-derived cells, 3D engineered tissues, lab instruments, and AI/ML data analysis, it gives biopharma teams functional human data earlier in development - aiming to bridge the gap between animal/2D-cell models and the clinic across cardiac, skeletal muscle, metabolic, and neuromuscular diseases.

- **Founded:** 2015
- **Headquarters:** Seattle, United States
- **Founders:** Nicholas A. Geisse (CEO (formerly Chief Science Officer)), Elliot Fisher (Co-founder & Chief Business Officer)
- **Team size:** ~58 employees (reported headcount; some press cites ~30-40)
- **Products:** Mantarray, Nautilus Plus / Nautilai, Stingray, NanoSurface Plates, Pulse
- **Notable:** Closed $10M Series B in December 2025 led by DreamCIS, Commercially launched the Mantarray 3D engineered muscle tissue contractility platform (2022), Spun out of the University of Washington (CoMotion Labs) and rebranded from NanoSurface Biomedical to Curi Bio

## Products & services

- **Mantarray** — A label-free electromagnetic platform that measures contractility of up to 24 3D engineered muscle tissues (cardiac and skeletal) in parallel.
- **Nautilus Plus / Nautilai** — Imaging platforms for high-content functional analysis of human iPSC-derived cells and tissues.
- **Stingray** — An electrical/mechanical stimulation system for long-term pacing and structural maturation of excitable cells and tissues in vitro.
- **NanoSurface Plates** — Biomimetic nanopatterned culture surfaces that mimic the extracellular matrix to drive structural maturation of cells.
- **Pulse** — Contractility and functional-data analysis software paired with the instrument platforms.
- **Curi Engine Services** — Fee-for-service compound profiling/screening, assay and tissue-model development, and discovery support for biopharma partners.

## Achievements

- Closed $10M Series B in December 2025 led by DreamCIS
- Commercially launched the Mantarray 3D engineered muscle tissue contractility platform (2022)
- Spun out of the University of Washington (CoMotion Labs) and rebranded from NanoSurface Biomedical to Curi Bio
- Built a customer roster of top-tier biopharma companies
- Formed the Celogics joint venture with NEXEL for iPSC-derived cell products

## Latest updates

- **2025-12** — Raised $10M Series B led by DreamCIS to scale human-relevant preclinical platforms and AI/ML data analysis.
- **2022-07** — Launched the Mantarray platform for label-free contractility analysis of 3D engineered muscle tissues.

## Links

- Website: https://curibio.com
- LinkedIn: http://www.linkedin.com/company/curibio
- Twitter/X: https://twitter.com/curi_bio
- Facebook: https://facebook.com/CuriBio/

---

Profile page: https://yespress.io/curi-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-15